Related references
Note: Only part of the references are listed.Assessment of Quality of Life Among Patients With Recurrent Clostridioides difficile Infection Treated with Investigational Oral Microbiome Therapeutic SER-109 Secondary Analysis of a Randomized Clinical Trial
Kevin W. Garey et al.
JAMA NETWORK OPEN (2023)
Impact of Clostridioides difficile infection on patient-reported quality of life
Zheyi Han et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2022)
Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial
Robert Orenstein et al.
BMC INFECTIOUS DISEASES (2022)
PCR150 Validation of a Health-Related Quality of Life Questionnaire in Patients with Recurrent Clostridioides Difficile Infection in Ecospor-III, a Phase 3 Randomized Trial
B Lapin et al.
VALUE IN HEALTH (2022)
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection
Sahil Khanna et al.
DRUGS (2022)
Recurrent Clostridioides difficile infection worsens anxiety-related patient-reported quality of life
Richard L. Hengel et al.
JOURNAL OF PATIENT-REPORTED OUTCOMES (2022)
1042. Safety of Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Individuals with Recurrent Clostridioides difficile Infection: Data from Five Prospective Clinical Studies
Tricia Braun et al.
Open Forum Infectious Diseases (2021)
167. Efficacy of Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Individuals with Recurrent Clostridioides difficile Infection: Data from Five Prospective Clinical Studies
Lindy Bancke et al.
Open Forum Infectious Diseases (2021)
The Contribution of Gut Microbiota-Brain Axis in the Development of Brain Disorders
Jessica Maiuolo et al.
FRONTIERS IN NEUROSCIENCE (2021)
The effect of a microbial ecosystem therapeutic (MET-2) on recurrent Clostridioides difficile infection: a phase 1, open-label, single-group trial
Dina Kao et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2021)
Risk Factors for Recurrence of Clostridioides difficile in Hospitalized Patients
Diaa Alrahmany et al.
JOURNAL OF INFECTION AND PUBLIC HEALTH (2021)
Clinical complications in patients with primary and recurrent Clostridioides difficile infection: A real-world data analysis
Paul Feuerstadt et al.
SAGE OPEN MEDICINE (2021)
Patient Experiences with Clostridioides difficile Infection: Results of a Canada-Wide Survey
Jens Vent-Schmidt et al.
PATIENT PREFERENCE AND ADHERENCE (2020)
Trends in US Burden of Clostridioides difficile Infection and Outcomes
Alice Y. Guh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Perception of quality of life in people experiencing or having experienced a Clostridioides difficile infection: a US population survey
Lise Lurienne et al.
JOURNAL OF PATIENT-REPORTED OUTCOMES (2020)
Quality of life and utility decrement associated with Clostridium difficile infection in a French hospital setting
Frederic Barbut et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2019)
Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)
L. Clifford McDonald et al.
CLINICAL INFECTIOUS DISEASES (2018)
Impaired Quality of Life, Work, and Activities Among Adults with Clostridium difficile Infection: A Multinational Survey
Kirstin Heinrich et al.
DIGESTIVE DISEASES AND SCIENCES (2018)
The importance of patient-reported outcomes in clinical trials and strategies for future optimization
Rebecca Mercieca-Bebber et al.
PATIENT-RELATED OUTCOME MEASURES (2018)
Efficacy and Safety of RBX2660 for the Prevention of Recurrent Clostridium difficile Infection: Results. of the PUNCH CD 2 Trial
Erik R. Dubberke et al.
Open Forum Infectious Diseases (2017)
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection
M. H. Wilcox et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Clinical and Healthcare Burden of Multiple Recurrences of Clostridium difficile Infection
Caroline Sheitoyan-Pesant et al.
CLINICAL INFECTIOUS DISEASES (2016)
Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study
Robert Orenstein et al.
CLINICAL INFECTIOUS DISEASES (2016)
Development and Validation of a Clostridium difficile Health-related Quality-of-Life Questionnaire
Kevin W. Garey et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2016)
Recurrent Clostridium difficile infection is associated with increased mortality
M. A. Olsen et al.
CLINICAL MICROBIOLOGY AND INFECTION (2015)
Burden of Clostridium difficile Infection in the United States
Fernanda C. Lessa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Absence of the gut microbiota enhances anxiety-like behavior and neuroendocrine response to acute stress in rats
Michele Crumeyrolle-Arias et al.
PSYCHONEUROENDOCRINOLOGY (2014)
Patients' Experience and Perception of Hospital-Treated Clostridium difficile Infections: a Qualitative Study
Isabelle Guillemin et al.
PATIENT-PATIENT CENTERED OUTCOMES RESEARCH (2014)
Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin
Oliver A. Comely et al.
CLINICAL INFECTIOUS DISEASES (2012)
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve
Javier A. Bravo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Share Paper
